- Company home
- Corporate objectives
- Company performance and financials
- Funding and venture capital
- Directors
Company latest
News and press
September 2009
New Product Launch – Ondansetron Oral Liquid…
Focus is pleased to announce the launch of Ondansetron Oral Liquid 4mg per 5ml to the market…
Full storyFunding and venture capital
Focus is backed by Matrix Private Equity Partners, a successful private equity investor based in the UK which has c. £120m under management.
Focus is constantly looking for acquisitions of tail products, either branded or generic in type, so that it can accelerate the growth of the business. Focus has the funding capability to take on product or portfolio acquisitions in excess of £10m.